VIJOICE 125 mg/1

VIJOICE 125 mg tablets are a pharmaceutical product containing alpelisib, used for specific medical conditions. This oral medication is manufactured by Novartis Pharmaceuticals Corporation in the USA.

VIJOICE 125 mg tablets are primarily used in the treatment of certain types of cancer. Alpelisib, the active ingredient, is often prescribed in combination with other therapies to target specific genetic mutations. Patients should consult their healthcare provider to determine if this medication is suitable for their condition.

Common effects of VIJOICE 125 mg tablets may include gastrointestinal issues, fatigue, and skin reactions. Some users might experience changes in blood sugar levels or appetite. It is important to monitor for any unusual symptoms and report them to a healthcare professional.

VIJOICE 125 mg tablets should be handled with care and stored as directed. Patients with a history of diabetes, liver, or kidney problems should discuss potential risks with their doctor. Pregnant or breastfeeding women should avoid this medication unless advised otherwise by a healthcare provider.

VIJOICE 125 mg tablets may interact with certain medications, including those metabolized by the liver's CYP3A enzyme system. Alcohol and other substances that affect liver function should be avoided. Always inform your healthcare provider about all medications and supplements you are taking.